Introduction
============

A systematic review and critical appraisal provides an unbiased and comprehensive synthesis of the best available scientific evidence related to a clinical issue of interest ([@b34-copd-2-241]; [@b26-copd-2-241]). Findings from a systematic review provide clinicians with an opportunity to examine this clinical evidence and its potential utility in the management of their own patients ([@b25-copd-2-241]).

Chronic obstructive pulmonary disease (COPD) is a term referring to a group of lung diseases characterized by fixed airflow obstruction. Exacerbations of COPD are associated with considerable physiologic deterioration and increased airway inflammatory changes that are caused by various factors such as viruses, bacteria, and possibly common pollutants.

Exacerbations of chronic obstructive pulmonary disease are now recognized to be an important cause of the considerable morbidity and mortality associated with COPD ([@b10-copd-2-241]).

Acute exacerbations are a common reason for hospital admissions and affects health-related quality of life (HRQL) ([@b32-copd-2-241]), and prognosis ([@b22-copd-2-241]). Its burden to society, as expressed in disability life years (DALYs), was ranked as eighth for men and seventh for women in 1996. It is predicted to rise to the fifth leading cause worldwide for both sexes by 2020 ([@b27-copd-2-241]). A small proportion of COPD patients, approximately 10%, experiencing acute exacerbations, accounts for over 70 percent of costs as a result of COPD due to emergency visits and hospitalizations ([@b28-copd-2-241]).

Identifying risk factors for hospitalization and re-admission have important health policy implications, but the knowledge of which factor causes or prevents exacerbation is very limited. The reasons for readmission and, more importantly, how readmissions can be prevented, are not clear.

Some potential factors for COPD exacerbations have been studied. The aim of this systematic review is to summarize the results from available studies to identify potential risk factors for hospital admission and or re-admission among patients experiencing COPD exacerbations. This maybe helpful in allowing us identify intervention strategies.

Materials and methods
=====================

Search strategy
---------------

The databases used for the selection of the literature were Medline (1966 to Oct 2006), Embase (1988 to Oct 2006), CINAHL, BIOSIS, PsycINFO and the Cochrane library. We did not restrict the search to COPD patients with exacerbation since exacerbation is not indexed as a Medical Subject Heading term (MeSH) for we feared that this could result in a narrow search and we may miss out relevant studies.

We used a broad search strategy using the terms "lung diseases obstructive", "chronic obstructive lung disease", "chronic obstructive pulmonary disease", "COPD exacerbation", "bronchitis", "emphysema", "risk factors", "hospitalization" and "readmission". We added other terms: "smoking", "LTOT", "physical activity" and "early therapy" to capture more studies. The electronic searches were supplemented by scanning the reference lists from retrieved articles to identify additional studies that may have been missed during the initial search.

Study selection
---------------

Cohort, retrospective and prospective, cross-sectional and case-control studies were included. We related the citation list to patients with COPD and COPD exacerbation by excluding articles with titles and/or abstracts indicating patients with COPD associated with other concomitant heart/lung disease. Our focus was on studies that analyzed the contribution of risk factors for exacerbation of COPD leading to admission and re readmission to hospital. Limiting our search to English language publications further reduced the list. Studies were selected for inclusion in the review according to definition for exacerbation of COPD, and admission/readmission. Two members of the review team independently scrutinized the titles and abstracts of all identified citations and ordered the full text of any article that was deemed potentially eligible by one of the reviewers. The two reviewers evaluated the full text of all retrieved papers, made a decision on inclusion or exclusion and discussed the decisions. Any disagreement was resolved by consensus with close attention to the inclusion/exclusion criteria.

Data extraction and quality assessment
--------------------------------------

We selected studies that included COPD exacerbations and the risk factors leading to admission/readmission to hospital. We independently extracted data from the included studies and resolved any differences by discussion. We used a quality scoring system to reduce the effects of confounding often encountered in retrospective and observational studies. We arbitrarily assigned 2 points for each fulfilled criterion (maximum, 10 points). We selected the median score of all the articles as a cutoff point to categorize good and poor quality studies. Authors met to compare assigned scores, and discrepancies were resolved by discussion.

Results
=======

Results of searches for documents
---------------------------------

Our primary search yielded more than 1500 articles. Reviewing titles and abstracts, 79 articles possibly fulfilled the inclusion criteria. Among them, 17 articles met the criteria and have been reviewed for this study ([@b19-copd-2-241]; [@b12-copd-2-241], [@b13-copd-2-241], [@b14-copd-2-241]); [@b23-copd-2-241], [@b24-copd-2-241]; [@b29-copd-2-241]; [@b20-copd-2-241]; [@b3-copd-2-241]; [@b15-copd-2-241]; [@b37-copd-2-241]; [@b11-copd-2-241]; [@b16-copd-2-241]; [@b35-copd-2-241]; ([@b36-copd-2-241]); [@b6-copd-2-241]; [@b7-copd-2-241]). The most common reason for exclusion was that it did not study "exacerbations" of COPD.

Study characteristics
---------------------

Of the seventeen epidemiological studies, nine were cohorts ([@b19-copd-2-241]; [@b20-copd-2-241]; [@b14-copd-2-241]; [@b15-copd-2-241]; [@b37-copd-2-241]; [@b35-copd-2-241]; [@b36-copd-2-241]; [@b16-copd-2-241]; [@b7-copd-2-241]), four were cross-sectional studies ([@b12-copd-2-241]; [@b23-copd-2-241], [@b24-copd-2-241]); [@b6-copd-2-241]), three were case-controls ([@b29-copd-2-241]; [@b13-copd-2-241]; [@b3-copd-2-241]) and one was a randomized clinical trial ([@b11-copd-2-241]). Seventy one percent were conducted in Europe, of these, 50% were from Spain. Three of the studies were conducted in Canada ([@b3-copd-2-241]; [@b11-copd-2-241] and [@b36-copd-2-241]).

The study characteristics and demographic of the participants of the included studies are shown in Tables [1](#t1-copd-2-241){ref-type="table"} and [2](#t2-copd-2-241){ref-type="table"}.

Heterogeneity of study designs, risk factors and outcomes restrict our result to only a systematic review and precluded a formal meta-analysis.

Case-control studies
--------------------

Three case-control studies were included ([@b29-copd-2-241]; [@b13-copd-2-241]; [@b3-copd-2-241]) (Table [1](#t1-copd-2-241){ref-type="table"}). The risk factors that were examined in these studies were: low BMI on admission, weight loss during hospitalization ([@b29-copd-2-241]), inhaled corticosteroids use previous admission ([@b3-copd-2-241]), lower FEV~1~ and under-prescription of LTOT ([@b13-copd-2-241]). In two studies, there were equal numbers of case and control subjects ([@b29-copd-2-241]; [@b13-copd-2-241]). Quality of reporting of case-control studies was evaluated using four questions including whether: exposure assessment was the same for cases and controls; exposure assessors were blind to case-control status; cases and controls were from the same population; and whether the number of and reasons for study withdrawals were reported (Table [3](#t3-copd-2-241){ref-type="table"}) ([@b29-copd-2-241]). Exposure assessments of cases and controls were assessed to be similar in all three studies ([@b29-copd-2-241]; [@b13-copd-2-241]; [@b3-copd-2-241]). As there was no explicit mention whether exposure assessors were blinded or not, we considered them as not blinded. Controls were assessed by the reviewers to be from the same population as the cases in all three studies. Information on withdrawals was reported only in one study ([@b13-copd-2-241]) while in the other study it was partially reported ([@b29-copd-2-241]). Again; these results suggest that there is a risk of bias, particularly interviewer bias, in these studies.

Cohort studies
--------------

There were 9 cohort studies included in the review (Table [1](#t1-copd-2-241){ref-type="table"}), ([@b19-copd-2-241]; [@b20-copd-2-241]; [@b14-copd-2-241]; [@b15-copd-2-241]; [@b37-copd-2-241]; [@b35-copd-2-241]; [@b36-copd-2-241]; [@b16-copd-2-241] and [@b7-copd-2-241]). The risk factors that were examined were physical activity, long term oral corticosteroid use, age, chronic hypercapnic respiratory failure, pulmonary hypertension, early therapy, hospital admission within 1 year before index admission, poor performance status, total length of stay in index admission \>5 days, nursing home residency, dependency in self-care activities, right heart strain pattern on electrocardiogram, on high dose inhaled corticosteroid, actual bicarbonate level \>25mmol, frequency of COPD exacerbation, living alone, not having a family doctor, anxiety, low FEV~1~ and low health status.

Quality of reporting of cohort studies was evaluated using five questions assessing whether: the studies were prospective or retrospective cohort; exposure assessment was the same for all participants; outcome assessment was the same for all participants; outcome assessors were blind to exposure status; and whether the number of and reasons for study withdrawals were reported ([@b21-copd-2-241]). The score for each question is reported in Table [4](#t4-copd-2-241){ref-type="table"}. We used the median of the scores to categorize the quality of studies. Based on the median 7, studies that scored seven or more were considered good ([@b19-copd-2-241]; [@b14-copd-2-241]; [@b15-copd-2-241]; [@b37-copd-2-241]; [@b35-copd-2-241]; [@b16-copd-2-241]; [@b7-copd-2-241]) and less than seven were considered poor quality ([@b20-copd-2-241] and [@b36-copd-2-241]).

Cross sectional studies
-----------------------

Four cross sectional studies were included in the review ([@b12-copd-2-241]; [@b23-copd-2-241], [@b24-copd-2-241]); [@b6-copd-2-241]). The risk factors that were examined in these studies were: no rehabilitation, poor inhaler maneuvers, no influenza vaccination, under prescription of LTOT, smoking, FEV~1~ impairment and significant comorbidity, disease duration \>5 yrs, use of psychotropic drugs, the increasing number of previous exacerbations, short acting beta-2 agonists, incomplete primary education and health status impairment. No quality assessment of the cross sectional studies were reported in this review.

Randomized control trial
------------------------

Only one RCT was included in this review ([@b11-copd-2-241]). The predictive factors of reduced hospitalization for the intervention (self-management) group in this study were sex (female), increased walking distance and higher education and risk factors of increased hospitalizations were older age and reduced health status.

The quality of this trial was assessed using standard criteria (allocation concealment, blinding, analysis by intention to treat, and completeness of follow-up) based on Jadad's quality scale ([@b17-copd-2-241]).

Risk factors for COPD exacerbation resulting in admission/readmission to hospital
---------------------------------------------------------------------------------

Among the many risk factors studied in this review, PaCO~2~ was reported by most studies (52%) ([@b19-copd-2-241]; [@b13-copd-2-241]; [@b20-copd-2-241]; [@b15-copd-2-241]; [@b35-copd-2-241]). Of these, one was case-control study ([@b13-copd-2-241]) and four were cohort studies ([@b19-copd-2-241]; [@b20-copd-2-241]; [@b15-copd-2-241]; [@b35-copd-2-241]).

Increased PaCO~2~ has proved to be an independent predictive factor of early hospital admission in two studies ([@b19-copd-2-241] and [@b20-copd-2-241]) and it has shown to be predictive of reduced survival in another study ([@b35-copd-2-241]). One study also reported PaCO~2~ to be significant in the univariate analysis, (p value 0.025) (OR 1.04, 95% confidence interval \[CI\] 1.01 to1.08) for hospitalization following an exacerbation of COPD ([@b13-copd-2-241]). But it was not found to be a risk factor for hospital readmission in another prospective study ([@b15-copd-2-241]).

Lower FEV~1~ was associated with higher risk of COPD readmission in four studies ([@b13-copd-2-241], [@b14-copd-2-241]); [@b16-copd-2-241]; [@b6-copd-2-241]). The result of a study by [@b23-copd-2-241], suggest that FEV~1~ impairment explains part of the risk of frequent exacerbations and hospital admissions. Three other studies also looked at FEV~1~% predicted at time of admission; however they did not find this to be a significant risk factor ([@b19-copd-2-241]; [@b12-copd-2-241]; [@b15-copd-2-241]).

Both oral and inhaled corticosteroids were studied as risk factors for COPD exacerbations ([@b13-copd-2-241], [@b14-copd-2-241]); [@b20-copd-2-241]; [@b3-copd-2-241]). Inhaled corticosteroid was a significant risk factor for early hospital admission in both univariate and multivariate analysis in a study by [@b20-copd-2-241]. The results from this study supports the previous trial by [@b4-copd-2-241], however no apparent influence from inhaled corticosteroids was found, even at moderate to high doses, on the likelihood of a subsequent hospitalization for COPD exacerbation in two case control studies ([@b13-copd-2-241]; [@b3-copd-2-241]).

Use of high dose oral corticosteroid was associated with a significantly increased risk of readmission in a cross sectional study at p value 0.006 with the (OR 1.55, 95% confidence interval \[CI\] 1.13 to 2.11) ([@b14-copd-2-241]). High dose systematic corticosteroid was reported as a significant factor for shorter time to readmission in the univariate analysis of a retrospective study ([@b20-copd-2-241]), and its long term use was reported as a risk factor of hospital readmission in a prospective cohort study ([@b15-copd-2-241]). Oral corticosteroid was related to a higher risk of admission in the crude analysis of a case control study ([@b13-copd-2-241]) but its lack of association in the adjusted model was interpreted as a marker of disease severity.

In a study by [@b14-copd-2-241] two variables: the highest tertile of usual physical activity and a higher score of physical quality of life showed a statistically significant reduced risk of readmission.

In another study by [@b13-copd-2-241] physical scale of health related quality of life was related to COPD admission in the crude analysis as in two previous studies ([@b18-copd-2-241]; [@b32-copd-2-241]) and maintained an association (although non significant) in the clinical model adjusted analysis. But this relationship after including dyspnea in this model was lost, indicating that physical quality of life and admission was confounded by dyspnea.

Dependency for assistance in self-care activities was shown to be an independent risk factor for shorter time to readmission in a retrospective study ([@b20-copd-2-241]). Both active and passive smoking was reported by some studies ([@b19-copd-2-241]; [@b12-copd-2-241], [@b13-copd-2-241], [@b14-copd-2-241]); [@b23-copd-2-241]) to be risk factors. One cross sectional study reported that being a former smoker exposed to passive smoking was associated with a significantly increased risk of readmission ([@b14-copd-2-241]).

In a multivariate logistic regression of a case-control study, current smoking was found to be a protective factor against COPD hospitalization (OR 0.30, p value 0.0222) ([@b13-copd-2-241]). However in two studies no association was found between current smoking and hospital admission ([@b19-copd-2-241], [@b23-copd-2-241]). Long Term use of Oxygen Therapy (LTOT) was reported as a risk factor in five studies ([@b19-copd-2-241]; [@b20-copd-2-241]; [@b13-copd-2-241], [@b14-copd-2-241]); [@b36-copd-2-241]).

[@b20-copd-2-241] reported that LTOT was associated with a shorter time to readmission (P \< 0.0001). Three other studies reported that LTOT significantly increased the risk of hospitalization for acute exacerbations of COPD ([@b19-copd-2-241]; [@b13-copd-2-241] et al; [@b36-copd-2-241]).

LTOT was also associated with a higher risk of readmission for COPD in a study by Garcia-Aymerich, but this did not reach statistical significance ([@b14-copd-2-241]).

In [@b13-copd-2-241] study, low body mass index (BMI) was associated with admission only in the univariate analysis. This was in agreement with another study conducted by [@b19-copd-2-241]. BMI on admission along with weight change during hospitalization were both significantly associated with unplanned early readmission in a study by [@b29-copd-2-241]. While in three other studies there were no significant association between BMI and hospital readmission ([@b23-copd-2-241]; [@b15-copd-2-241]; [@b6-copd-2-241]).

Total length of stay in the index admission of more than 5 days and nursing home residency were the other significant risk factors for early readmission reported by [@b20-copd-2-241]. This study also reported that hospital admission within one year before the index admission was a significant risk factor for re admission (p \< 0.0001). Similarly having more than three COPD admissions in the year before recruitment was found to be associated with an increased risk of readmission, in two studies by [@b13-copd-2-241], [@b14-copd-2-241] and a recent study by [@b7-copd-2-241]. In contrast to these findings, no association was found between the number of previous hospital admissions and unplanned early readmission in a retrospective study by [@b29-copd-2-241].

Patients with a longer history of having a COPD diagnosis (more than 5 years) were found to be approximately twice as likely to have frequent readmissions than those with a shorter duration (OR = 2.51, 95% confidence interval \[CI\] 1.39 to 4.53) ([@b6-copd-2-241]).

Co-morbid conditions such as right heart strain on ECG, coronary artery disease, left ventricular failure, diabetes mellitus, were also found to be significant risk factors for admission in the same study ([@b20-copd-2-241]) as well as in another cross sectional study ([@b23-copd-2-241]). However, surprisingly the presence of comorbidity was not found to be significantly associated with readmission in four other studies ([@b29-copd-2-241]; [@b14-copd-2-241]; [@b15-copd-2-241] and [@b6-copd-2-241]).

Older age was considered as a risk factor for hospitalization in two studies ([@b35-copd-2-241]; [@b11-copd-2-241]) but in another study was not associated with an increased risk ([@b19-copd-2-241]). It was also associated with a shorter time to first readmission after discharge in another study ([@b20-copd-2-241]). Age related deficiencies in process of care did not predict inpatient or readmission in the recent high sample size study by [@b7-copd-2-241].

Female gender was reported as a predictive factor for reduced hospitalization in a multicenter, randomised controlled trial ([@b11-copd-2-241]), but neither age nor gender was found to be an related to COPD admission in a study by [@b13-copd-2-241]. Low health status was found to be an important risk factor for both admission and readmission of COPD patients who experienced an exacerbation ([@b16-copd-2-241]; [@b24-copd-2-241]; [@b11-copd-2-241]). In a retrospective cohort study it has been reported that patients with poor health related quality of life (HRQoL) had frequent ER visits and readmissions to hospital ([@b36-copd-2-241]). [@b37-copd-2-241] demonstrated that patients who habitually fail to seek therapy for their exacerbations have worse HRQoL and are more likely to be hospitalized for the management of an exacerbation. This supports the results and their other study that the patients who had no family doctor were predisposed to readmission (OR 1.435, 95% confidence interval \[CI\] 0.14 to1.34), p value 0.008) ([@b36-copd-2-241]).

Patients with severe dyspnea have been found to be more likely to be readmitted to hospital in a univariate analysis (OR = 1.87, 95% confidence interval \[CI\] 0.98 to 3.28) ([@b6-copd-2-241]).This supports the results of a retrospective cohort study that patients with severe dyspnea and frequent COPD exacerbations had frequent emergency visits and readmissions to hospital ([@b36-copd-2-241]). In an earlier study it has been shown that patients with dyspnea of grade 2 never experienced hospital admissions for acute exacerbation, but with a dyspnea of grade 3, 4 or 5 they had a significant risk of hospitalization at one year ([@b19-copd-2-241]).

Characteristics of the risk or protective factors included in this review are shown in [Appendix 1](#app1){ref-type="app"}.

Discussion
==========

This systematic review evaluated the results of 17 studies for risk factors for admission or readmission in COPD patients who had experienced an exacerbation. Variables including using long term oxygen therapy, having low health status or poor health related quality of life and not having routine physical activity were all associated with an increased risk of admission and readmission to hospital.

PaCO~2~ was shown to be an independent risk factor for hospital admission for an acute exacerbation of COPD. Higher levels of PaCO~2~ likely represents a marker of disease severity or less likely that patients with chronic hypercapnia, and hence raised actual bicarbonate, are probably more easily symptomatic than normocapnic patients because of their rapid and shallow breathing pattern ([@b30-copd-2-241]), resulting in earlier and more frequent need for acute care.

In this review, three predictive factors: "previous hospital admission", "dyspnea" and "oral corticosteroids" were all found to be significant risk factors of readmissions. Oral corticosteroids are often used in the treatment of acute exacerbations of COPD. In contrast, studies of the utility of inhaled corticosteroids in COPD patients who require hospital admission or emergency department treatment provide conflicting results, with some studies reporting improvement and others reporting no effect. This inconsistency suggests that the results of ongoing clinical trials, designed to look at the specifically possible benefits of inhaled corticosteroids on the risk of exacerbation, should be awaited before recommending their routine use in COPD patients. The most recent such study, paradoxically showed an increased risk of pneumonia in patients with COPD ([@b5-copd-2-241]).

In some studies use of long-term home of supplemental oxygen (LTOT) was independently associated with admission or shorter time to first readmission for acute exacerbations of COPD. However in other studies, this association was not significant or it did not remain significant after adjustment, indicating that LTOT could be probably a marker of severity in those patients.

The negative association between current smoking and hospital admission was explained by [@b2-copd-2-241] in that many severely ill patients with COPD spontaneously quit smoking in response to their symptoms and disability, and it is hardly surprising that these patients do not do well afterwards. For this reason studies of patients with well established disease have often not shown a reduction in admission with smoking cessation.

Prospective studies including a wider range of COPD severity would be helpful to clarify this issue.

Low body mass index (BMI) was associated with admission and non elective readmission and consistently with its relation to prognosis of COPD in three studies ([@b19-copd-2-241]; [@b29-copd-2-241]; [@b13-copd-2-241]). It is not clear whether the observed relationships between both low body weight on admission and early readmission are causal relationships or whether these parameters represent epiphenomena of more severe disease. There is a hypothesis that tissue depletion in patients with COPD may be related in part to a systemic catabolic response induced by inflammation, which cannot completely be reversed by nutritional support only ([@b31-copd-2-241]). Further studies are indicated to confirm this hypothesis.

In this review, the presence of coexisting comorbidites was not associated with an increased probability of frequent exacerbations, but with an increased risk of admission. This suggests that comorbidity does not appear to be a risk factor for frequent exacerbations, but a risk factor for severe life threatening exacerbations that can provoke admission. We believe that potentially all co-morbidities are important contributing factors to COPD morbidity, and special attention should be paid to the diagnosis of coexisting disease and its association with COPD admission.

Patients with COPD who perform a relatively high level of physical activity in their daily life have been shown a substantially reduced risk of readmission due to exacerbation ([@b13-copd-2-241]; [@b20-copd-2-241]).The explanation could be that exercise engages cardiovascular system and helps the body to deliver oxygen to respiratory muscles more efficiently. In addition, endurance training can reduce exercise induced lactic acidosis and improve the oxidative capacity of the muscles in patients with moderate to severe COPD. Therefore such muscles would be more able to tolerate a COPD exacerbation than untrained muscles.

Longer length of stay, nursing home residents ([@b20-copd-2-241]), taking anticholinergics ([@b14-copd-2-241]), increasing age and chronic mucus hypersecretion (CMH) ([@b23-copd-2-241]), were the other factors associated with early readmission.

Being managed by a respirologist was also associated with higher risk of readmission, contrary to what might have been expected, and it was not totally removed after adjustment for previous admission, suggesting that other mechanisms may be operating. However, in another study ([@b37-copd-2-241]), it has been demonstrated that prompt treatment by a physician is associated with better outcomes.

Older age was associated with shorter time to first readmission and increased risk of hospitalization in several studies ([@b20-copd-2-241]; [@b35-copd-2-241]; [@b11-copd-2-241]). This may be related to the higher degree of disability and comorbidity in the older population.

Patients who habitually fail to seek therapy for their exacerbations have worse health-related quality of life and are more likely to be hospitalized for the management of an exacerbation. Patients with more symptoms at exacerbation onset tended to present earlier for treatment, and those exacerbations with more symptoms were indeed more severe, as they took longer to recover. Therefore, the milder and less symptomatic exacerbations were in fact presenting slightly later, and when this effect is taken into account, the benefit of early treatment became more pronounced.

In conclusion, our results for this systematic review suggest that there are a number of potential modifiable factors that are independently associated with the higher risk of COPD exacerbation requiring admission/readmission to hospital. Identifying these factors and the development of targeted interventions could potentially reduce the number and severity of such exacerbations.

Limitations of our study
========================

We reviewed only published studies, and unpublished studies may contain valid results that conflict with our conclusions. This is of particular concern in a systematic review of observational studies as there is a greater tendency towards publication bias than there is with randomised controlled trials ([@b9-copd-2-241]).

We did not search the gray literature (ie, literature that is difficult to identify, locate and retrieve, examples would include theses, proceedings of workshops etc) extensively. We included only English language papers and since in this review most of the articles were studied and published in Europe, we might have missed some non-English related articles and also we may have overestimated the methodological limitations of the included studies because we relied on published reports.

There is a chance that we may have missed other studies because of these limitations, but considering the broad nature of our search strategy and the number of citations screened, we believe this risk to be small. In addition, the included studies may have suffered from other design weaknesses such as confounding by variables other than sample size problems, which we did not address. Our challenge in categorizing study design and assigning primary outcomes certainly suggest that design was an issue. To avoid selection bias, a systematic and comprehensive search was conducted and two reviewers independently evaluated trials for inclusion. Because of the wide variation in end points and study design we were not able to do a formal meta analysis.

Implications for policy makers and future research
==================================================

The evidence related to hospital admission and readmission is currently equivocal and requires further study. Several potentially important outcomes including patients' satisfaction, self management, patients' coping and adherence, smoking cessation, and the effects on social function have not been fully evaluated. There is also a need to evaluate the economic implications of COPD exacerbations and especially hospitalizations.

###### 

Characteristics of the risk/protective factors studied in this systematic review

  **Risk/Protective Factors**                          **First author**    **No. of patients**   **Crude HR/OR/RR (95%CI)**   **P-value**          **Adjusted HR/OR/RR (95%CI)**   **Adjusted p-value**   **Outcome[\*](#tfn4-copd-2-241){ref-type="table-fn"} A,R,E**
  ---------------------------------------------------- ------------------- --------------------- ---------------------------- -------------------- ------------------------------- ---------------------- --------------------------------------------------------------
  **Hospital admission in the previous year**          [@b14-copd-2-241]   340                   2.27 (1.69--3.04)            0.000                --                              --                     R
  [@b13-copd-2-241]                                    172                 3.82 (1.14--2.75)     0.030                        6.21 (1.60--24.07)   0.008                           A                      
  [@b20-copd-2-241]                                    551                 1.55 (1.22--1.98)     \<0.001                      --                   --                              R                      
  [@b16-copd-2-241]                                    416                 1.98 (1.42--2.76)     --                           --                   \-                              R                      
  [@b7-copd-2-241]                                     7514                --                    --                           --                   --                              R                      
  **PCO~2~**                                           [@b13-copd-2-241]   172                   1.04 (1.01--1.08)            0.025                --                              --                     A
  [@b20-copd-2-241]                                    551                 --                    0.007                        --                   --                              R                      
  [@b19-copd-2-241]                                    64                  2.1 (1.4--3.1)        0.0003                       --                   --                              A                      
  **FEV1 Pred%**                                       [@b13-copd-2-241]   172                   0.97 (0.95--0.99)            0.002                0.96 (0.93--0.98)               0.000                  A
  [@b14-copd-2-241]                                    340                 0.97 (0.96--0.98)     0.000                        0.97 (0.96--0.99)    0.001                           R                      
  [@b23-copd-2-241]                                    713                 --                    −0.72 (0.58--0.88)                                --                              A                      
  [@b6-copd-2-241]                                     186                 2.60 (1.18--5.74)     0.018                        --                   --                              R                      
  [@b36-copd-2-241]                                    54                  2.08 (0.01--0.77)     0.003                        --                   --                              E                      
  [@b16-copd-2-241]                                    416                 0.83 (0.76--0.91)     --                           --                   --                              R                      
  **LTOT**                                             [@b13-copd-2-241]   172                   --                           --                   22.6 (2.31--21.88)              0.007                  A
  [@b14-copd-2-241]                                    340                 2.36 (1.79--3.11)     0.000                        1.26 (0.87--2.05)    0.223                           R                      
  [@b20-copd-2-241]                                    551                 --                    \<0.0001                     --                   --                              A                      
  [@b24-copd-2-241]                                    1057                3.47 (2.35--5.12)     \<0.0001                     --                   --                              A                      
  [@b36-copd-2-241]                                    54                  4.85 (1.33--17.75)    0.014                        --                   --                              E                      
  **Health status impairment**                         [@b24-copd-2-241]   1057                  1.01 (1.00--1.02)            0.0008               --                              --                     A
  **Comorbidity**                                      [@b20-copd-2-241]   551                   1.56 (1.19--2.04)            0.001                --                              --                     R
  [@b24-copd-2-241]                                    713                 --                    --                           1.97 (1.24--3.14)    --                              A                      
  [@b36-copd-2-241]                                    54                  0.66 (0.45--0.96)     0.031                        --                   --                              E                      
  **Oral corticosteroids**                             [@b14-copd-2-241]   340                   1.55 (1.13--2.11)            0.006                1.59 (1.07--2.37)               0.021                  R
  [@b15-copd-2-241]                                    171                 --                    0.0026                       --                   --                              R                      
  [@b20-copd-2-241]                                    551                 --                    0.0151                       --                   --                              R                      
  **Inhaled corticosteroid**                           [@b20-copd-2-241]   551                   1.35 (1.02--1.80)            0.036                --                              --                     R
  [@b24-copd-2-241]                                    1057                --                    \<0.0001                     --                   --                              A                      
  **BMI**                                              [@b29-copd-2-241]   28                    --                           0.046                --                              --                     R
  [@b13-copd-2-241]                                    172                 0.92 (0.86--0.99)     0.023                        --                   --                              A                      
  [@b19-copd-2-241]                                    64                  --                    0.015                        --                   --                              A                      
  **Current smoking**                                  [@b13-copd-2-241]   172                   0.46 (0.20--1.01)            0.053                0.45 (0.19--1.05)               0.063                  A
  [@b16-copd-2-241]                                    416                 0.78 (0.55--1.10)     --                           --                   --                              R                      
  **Older age**                                        [@b20-copd-2-241]   551                   --                           0.0013               --                              --                     R
  Soler-Cataluna 2006                                  304                 --                    --                           4.52 (2.31--8.83)    \<0.001                         A                      
  [@b36-copd-2-241]                                    54                  0.91 (0.85--0.97)     0.0028                       --                   --                              E                      
  [@b11-copd-2-241]                                    191                 --                    --                           1.05 (1.03--1.06)    --                              E                      
  **Living alone**                                     [@b24-copd-2-241]   1057                  --                           0.007                --                              --                     A
  [@b36-copd-2-241]                                    54                  0.60 (0.00--0.82)     0.0092                       --                   --                              R                      
  **Physical activity/Scale**                          [@b13-copd-2-241]   172                   0.96 (0.93--0.99)            0.02                 0.97 (0.94--1.01)               0.104                  A
  [@b20-copd-2-241]                                    551                 1.40 (1.06--1.83)     0.0001                       --                   --                              R                      
  **Health related**                                   [@b14-copd-2-241]   340                   0.46 (0.32--0.68)            0.000                0.49 (0.31--0.79)               0.003                  R
  **QoL[\*](#tfn4-copd-2-241){ref-type="table-fn"}**                                             0.97 (0.95--0.98)            0.000                0.98 (0.96--0.99)               0.007                  R
  **Dyspnea**                                          [@b6-copd-2-241]    186                   1.80 (0.98--3.28)            \<0.05               --                              --                     R
  **Family doctor**                                    [@b36-copd-2-241]   54                    1.44 (0.14--1.34)            0.008                --                              --                     R
  4.06 (1.06--10.51)                                   0.041               --                    --                           E                                                                           
  **Pulmonologist**                                    [@b14-copd-2-241]   340                   2.16 (1.43--3.27)            0.000                1.77 (1.07--2.92)               0.025                  R
  **Influenza vaccination**                            [@b6-copd-2-241]    186                   8.14 (1.77--37.47)           0.002                --                              --                     R

Outcome: A= Admission; R= Readmission, E= Exacerbation, QoL= Quality of Life

###### 

Study Characteristics of the included studies

  **No.**   **First author, Year**   **Country of origin**   **Study design**   **Risk/protective factors**                                                                                                                                                                   **Outcome**
  --------- ------------------------ ----------------------- ------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------
  1         [@b29-copd-2-241]        Netherlands             C-C                Low BMI on admission, Weight loss during hospitalization                                                                                                                                      Readmission
  2         [@b3-copd-2-241]         Canada                  C-C                Inhaled corticosteroids                                                                                                                                                                       Hospitalization
  3         [@b13-copd-2-241]        Spain                   C-C                Previous admissions, lower FEV~1~, LTOT                                                                                                                                                       Hospitalization
  4         [@b14-copd-2-241]        Spain                   P-C                Physical activity                                                                                                                                                                             Readmission
  5         [@b15-copd-2-241]        Netherlands             P-C                Younger Age, long term oral corticosteroid                                                                                                                                                    Readmission
  6         [@b19-copd-2-241]        France                  P-C                Chronic hypercapnic respiratory insufficiency, pulmonary hypertension                                                                                                                         Hospitalization
  7         [@b37-copd-2-241]        U.K                     P-C                Early therapy                                                                                                                                                                                 Hospitalization
  8         [@b35-copd-2-241]        Spain                   P-C                Older age, PaCO~2~                                                                                                                                                                            Hospitalization
  9         [@b16-copd-2-241]        Nordic                  P-C                Anxiety, low FEV~1~, low health status                                                                                                                                                        Readmission
  10        [@b7-copd-2-241]         U.K                     P-C                Previous admission, poor performance                                                                                                                                                          Readmission
  11        [@b20-copd-2-241]        China                   R-C                Pre hospital admission, length of stay \>5 days, nursing home residency, self-care activities, right heart strain pattern on ECG, inhaled corticosteroid, bicarbonate level \>25 mmoll^--1^   Readmission
  12        [@b36-copd-2-241]        Canada                  R-C                Living alone, frequency of COPD exacerbation, not having a family doctor                                                                                                                      Readmission
  13        [@b12-copd-2-241]        Spain                   C-S                No rehabilitation, poor inhaler maneuvers, no influenza vaccination, LTOT, smoking                                                                                                            Hospitalization
  14        [@b23-copd-2-241]        Spain                   C-S                FEV1 impairment, significant comorbidity                                                                                                                                                      Hospitalization
  15        [@b6-copd-2-241]         Singapore               C-S                Disease duration \>5 yrs, FEV1 \< 50% predicted, use of psychotropic drugs, vaccination status                                                                                                Readmission
  16        [@b24-copd-2-241]        Spain                   C-S                Use of LTOT, increasing the number of previous exacerbations, short acting beta-2 agonists, incomplete primary education, impairment in health status                                         Hospitalization
  17        [@b11-copd-2-241]        Canada                  RCT                Sex (female), increased walking distance, higher education, older age, reduced health status                                                                                                  Hospitalization

R-C = retrospective-cohort, P-C = prospective-cohort, C-S = cross--sectional, C-C = case--control, RCT = randomised control trial

###### 

Demographic characteristics of the included studies

  **Study design/First author/year**                      **Sample size (n)**                                  **Age (years)**                             **Gender Male (%)**   
  ------------------------------------ ------------------ --------------------- ------------------ ----------- ------------------ ------------- ---------- --------------------- -------------
  **Case-control**                     **Case**                                 **Control**        **Case**                       **Control**   **Case**                         **Control**
                                                                                                                                                                                 
  [@b29-copd-2-241]                    14                                       14                 71 (9)                         69 (5)        57                               57
  [@b3-copd-2-241]                     843                                      11030              76 (8)                         76 (7)        66                               62
  [@b13-copd-2-241]                    86                                       86                 70 (8)                         69 (9)        91                               91
  **Cohort/cross sectional**                                                                                                                                                     
  [@b14-copd-2-241]                                       340                                                  69 (9)                                      92                    
  [@b20-copd-2-241]                                       551                                                  74 (9)                                      77                    
  Soler-Cataluna 2006                                     304                                                  71 (9)                                      100                   
  [@b37-copd-2-241]                                       128                                                  67 (7)                                      69                    
  [@b19-copd-2-241]                                       64                                                   64 (9)                                      84                    
  [@b15-copd-2-241]                                       171                                                  71 (9)                                      61                    
  [@b12-copd-2-241]                                       353                                                  69 (9)                                      92                    
  [@b23-copd-2-241]                                       1001                                                 70 (10)                                     89                    
  [@b6-copd-2-241]                                        186                                                  75 (25)                                     83                    
  [@b24-copd-2-241]                                       1057                                                 67 (9)                                      95                    
  [@b36-copd-2-241]                                       54                                                   71 (10)                                     61                    
  [@b16-copd-2-241]                                       406                                                  69 (11)                                     49                    
  [@b7-copd-2-241]                                        7514                                                 71(10)                                      52                    
  **RCT**                              **Intervention**   **usual**             **Intervention**   **usual**   **Intervention**   **usual**                                      
  [@b11-copd-2-241]                    96                 95                    69 (7)             70 (7)      52                 59                                             

Age: Mean (SD)

###### 

A quality scoring system for case-control studies

  **First author**    **Was exposure assessment the same for cases and controls?**   **Were exposure assessors blind to case-control status?**   **Were cases and controls from the same population?**   **Were the number and reasons for study withdrawals reported?**
  ------------------- -------------------------------------------------------------- ----------------------------------------------------------- ------------------------------------------------------- -----------------------------------------------------------------
  [@b29-copd-2-241]   2                                                              0                                                           2                                                       1
  [@b3-copd-2-241]    2                                                              0                                                           2                                                       0
  [@b13-copd-2-241]   2                                                              0                                                           2                                                       2

###### 

A quality scoring system for cohort studies

  **First author**    **P (2), R (1)**   **Was exposure assessment the same for all participants?**   **Was outcome assessment the same for all participants?**   **Were outcome assessors blind to exposure status?**   **Were the number of and reasons for study withdrawals reported?**
  ------------------- ------------------ ------------------------------------------------------------ ----------------------------------------------------------- ------------------------------------------------------ --------------------------------------------------------------------
  [@b20-copd-2-241]   1                  1                                                            2                                                           1                                                      1
  [@b19-copd-2-241]   2                  1                                                            2                                                           1                                                      2
  [@b37-copd-2-241]   2                  1                                                            2                                                           1                                                      2
  [@b14-copd-2-241]   2                  2                                                            2                                                           1                                                      2
  [@b15-copd-2-241]   2                  1                                                            2                                                           1                                                      2
  [@b35-copd-2-241]   2                  2                                                            0                                                           1                                                      2
  [@b36-copd-2-241]   1                  1                                                            1                                                           0                                                      2
  [@b16-copd-2-241]   2                  1                                                            1                                                           1                                                      2
  [@b7-copd-2-241]    2                  1                                                            1                                                           2                                                      1

R = retrospective, P = prospective
